Today: 23 January 2026
Subscribe
Browse Category

Company Analysis News 27 June 2025 - 30 September 2025

Crown Electrokinetics (CRWV/CRKN) Surges Amid Takeover Buzz – Key Facts & Analysis (Sept 30, 2025)

Crown Electrokinetics (CRWV/CRKN) Surges Amid Takeover Buzz – Key Facts & Analysis (Sept 30, 2025)

Recent Corporate Developments In mid-2025 Crown has executed several strategic shifts. The $3.15/share merger agreement (announced June 9) commits Crown to become a private subsidiary; the tender offer is expected to open soon with no financing condition Businessinsider Businessinsider. The special committee judged the price fair and the transaction almost certain after shareholders tender Businessinsider. Alongside this, on July 23…
30 September 2025
·····
Wolfspeed (WOLF) Stock Skyrockets 1,100% on Shocking Chapter 11 Reorganization

Wolfspeed (WOLF) Stock Skyrockets 1,100% on Shocking Chapter 11 Reorganization

Stock Performance (Sep 29, 2025 & Recent) Wolfspeed’s share price was relatively stable (around $1–$2) in early September after its Chapter 11 filing in June. On Sept 9, shares jumped ~48% to $1.82 when the court confirmed the reorganization plan. After trading near that level for weeks, Sep 29 brought unprecedented volatility. Speculation and heavy buying drove WOLF sharply higher:…
29 September 2025
····
Wolfspeed’s Wild Ride: From Bankruptcy Plans to EV Boom – What’s Next for WOLF Stock?

Wolfspeed’s Wild Ride: From Bankruptcy Plans to EV Boom – What’s Next for WOLF Stock?

Stock Performance Wolfspeed’s stock has been extremely volatile in 2025. It hit 27-year lows in March amid concerns over CHIPS Act funding, then rallied sharply after filing for restructuring. Notably, Sep 9, 2025 saw WOLF pop nearly 48% (to $1.82) when a U.S. court confirmed its pre-packaged Chapter 11 plan Reuters. However, this rally proved short-lived. In the following weeks, the…
29 September 2025
····
SPRC Rockets 59% After “Quantum Leap”: What Really Drove SciSparc’s Two‑Day Surge (Sept. 25–26) — And What Comes Next

SPRC Rockets 59% After “Quantum Leap”: What Really Drove SciSparc’s Two‑Day Surge (Sept. 25–26) — And What Comes Next

Key facts (Sept. 25–26, 2025) What happened — and why it matters SciSparc’s new program aims to apply quantum algorithms to hard problems in protein folding and protein–ligand interactions, with the goal of more precise simulations that speed discovery in neurological and rare diseases. The board authorized creating a wholly‑owned Israeli subsidiary to run the effort and to pursue IP around…
26 September 2025
····
RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

RGC Stock Skyrockets 11,000% – Inside Regencell Bioscience’s Wild 2025 Ride

In-Depth Report on RGC Stock as of September 25, 2025 Company Background & Fundamentals Regencell Bioscience’s Hong Kong office. The company is an early-stage biotech leveraging Traditional Chinese Medicine for neurological disorders. Founded in 2014 and listed on Nasdaq in 2021, Regencell focuses on developing natural TCM-based treatments for conditions like ADHD and autism spectrum disorder Marketbeat. It has even…
25 September 2025
····
Fluence Energy (FLNC) Skyrockets on Mega Battery Deal – Inside the Rally and What’s Next

Fluence Energy (FLNC) Skyrockets on Mega Battery Deal – Inside the Rally and What’s Next

Fluence Energy (FLNC) Stock and Company Analysis on September 24, 2025 Stock Performance in Late September 2025 Fluence Energy’s stock went on a tear in the days around September 24, 2025. The share price exploded from the upper $7 range to the $11–12 range within a week Stockanalysis. On Wednesday, Sept 24, FLNC closed around $11.24, roughly 10% higher than…
24 September 2025
····
Apple vs. Samsung – 2025’s Epic Stock Showdown: Which Tech Giant is the Better Bet?

Apple vs. Samsung – 2025’s Epic Stock Showdown: Which Tech Giant is the Better Bet?

2025 Year-to-Date Stock Performance Apple and Samsung have experienced starkly different stock trajectories in 2025. Apple’s stock (AAPL) has essentially moved sideways year-to-date – by mid-September 2025 it was roughly flat, even slightly down about 1% for the year Statmuse after a strong run in 2023. In contrast, Samsung Electronics (005930.KS) has seen a blockbuster rally in its share price.…
21 September 2025
····
AI Stocks Soar as Nvidia Hits $4T, Apple Feels the Heat, and Musk Doubles Down – Daily Roundup

AI Stocks Soar as Nvidia Hits $4T, Apple Feels the Heat, and Musk Doubles Down – Daily Roundup

Nvidia briefly hit a $4 trillion market capitalization last week, with shares rising to an all-time high of $164.42. Nvidia’s value has roughly tripled in about a year after first crossing $1 trillion in mid-2023. Microsoft closed Monday at $503.51 as part of the AI rally lifting the Magnificent 7. Apple is down about 16% year-to-date, erasing more than $630…
14 July 2025
····
NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook

NVIDIA 2025: Dominating the AI Boom – Company Overview, Key Segments, Competition, and Future Outlook

Recent News and Highlights (Mid-2025) Table 1 – NVIDIA’s Explosive Revenue Growth (Fiscal year ends late January; FY2025 covers Feb 2024–Jan 2025) Fiscal Year Annual Revenue (USD) YoY Growth FY2023 (ended Jan 2023) $26.97 billion Macrotrends Macrotrends +0.2% Macrotrends (flat) FY2024 (ended Jan 2024) $60.92 billion Macrotrends Macrotrends +125.9% Macrotrends FY2025 (ended Jan 2025) $130.50 billion Nvidia Macrotrends +114.2% Macrotrends NVIDIA’s revenues more than doubled in both FY2024…
27 June 2025
··
1 … 64 65 66

Stock Market Today

  • Oric Pharmaceuticals Shares Poised for 74% Upside as Biotech Innovation Draws Investor Attention
    January 23, 2026, 8:13 AM EST. Oric Pharmaceuticals (NASDAQ: ORIC) is gaining investor interest with a potential 74% upside from its current $12.05 share price, backed by partnerships with Pfizer, Bayer, and Johnson & Johnson. The clinical-stage biotech focuses on therapies addressing cancer treatment resistance, advancing candidates like ORIC-114 and ORIC-944 through early-stage trials. Despite a $1.17 billion market cap, Oric reports a negative EPS of -1.71 and free cash flow of -$70.7 million, reflecting typical high-risk biotech dynamics. With no dividends and a neutral RSI, stock momentum shows cautious optimism. Analysts rate ORIC with 14 buys and project a $21 average target price, suggesting substantial growth for investors able to tolerate the sector's inherent uncertainties.
Go toTop